211. 左心低形成症候群 Hypoplastic left heart syndrome Clinical trials / Disease details
臨床試験数 : 22 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04925024 (ClinicalTrials.gov) | June 25, 2021 | 8/6/2021 | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. | Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. | Hypoplastic Left Heart Syndrome | Biological: Lomecel-B medicinal signaling cells | Ann & Robert H Lurie Children's Hospital of Chicago | National Heart, Lung, and Blood Institute (NHLBI);The University of Texas Health Science Center, Houston;Longeveron Inc. | Recruiting | N/A | 12 Months | All | 38 | Phase 2 | United States |